XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2022
Jan. 31, 2020
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Significant Accounting Policies [Line Items]                    
Letter of credit related to lease of real property     $ 300,000       $ 300,000      
Accumulated deficit     157,879,373       157,879,373   $ 141,074,640  
Cash and cash equivalents     13,664,101   $ 32,070,612   13,664,101 $ 32,070,612 34,669,605 $ 51,674,087
Deferred grant funding     13,694,085       13,694,085   $ 18,303,567  
Working capital deficit     2,500,000       2,500,000      
Net loss     8,762,232 $ 8,042,501 (413,998) $ 8,398,670 16,804,733 7,984,672    
Cash flow from operations             $ 22,700,000      
Period of insufficient cash and liquidity requirements             12 months      
License and collaboration revenue     $ 0   $ 10,000,000   $ 0 $ 10,000,000    
Bayer Healthcare License Agreement                    
Significant Accounting Policies [Line Items]                    
Upfront license fee paid   $ 1,000,000                
License and collaboration revenue   20,000,000                
Milestone payments, contingent amount   $ 310,000,000                
Organon                    
Significant Accounting Policies [Line Items]                    
Upfront license fee paid $ 10,000,000           10,000,000      
Milestone payments, contingent amount             $ 182,500,000